“We believe the time is right to harness advances in machine learning to discover the next generation of biologics drugs to improve the lives of patients with autoimmune diseases.” – Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic.

Seismic Therapeutic has successfully concluded a $121 million Series B financing round, led by Bessemer Venture Partners and featuring participation from new investors such as Amgen Ventures, Codon Capital, and others, alongside existing investors. This funding brings the total capital raised by the machine learning immunology company to $222 million.

The proceeds will be allocated to advancing Seismic’s two lead programs, S-1117 (pan-IgG protease sculpting enzyme) and S-4321 (PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional antibody), through Phase 1 proof-of-mechanism trials. Additionally, the funding will facilitate the expansion of Seismic’s biologics pipeline and further development of its IMPACT platform, integrating machine learning to enhance drug discovery in immunology. (Businesswire)

The company’s unique approach combines machine learning with deep drug development expertise to address unmet medical needs in autoimmune diseases. Andrew Hedin from Bessemer Venture Partners will join Seismic’s board of directors as part of the financing collaboration.

Jo Viney, Founder, President, and CEO of Seismic, said the company was pioneering a new era of immunology drug development through machine learning integration.

Seismic, headquartered in the Boston biotechnology hub, focuses on transforming immunology therapy discovery and development through innovative machine learning methodologies. The IMPACT platform, central to Seismic’s strategy, employs machine learning to parallelize various drug discovery components, enabling the accelerated design and analysis of proteins and protein modifications.

This approach aims to create novel biologics with superior properties, simultaneously optimizing for biologic function, reduced immunogenicity, and developability.

Related Story:  Rapport Therapeutics Raises $150 Million For Precision Neuromedicines